Multi-center clinical study to investigate the ratio of patients who have achieved Complete Molecular Response (CMR) detected based on major BCR-ABL mRNA quantitative PCR assay (international scale), among patients with chronic myelogenous leukemia in chronic phase who achieved Major Molecular Response (MMR)
Not Applicable
- Conditions
- Chronic myelogenous leukemia
- Registration Number
- JPRN-UMIN000004935
- Lead Sponsor
- CMR Study Group
- Brief Summary
CMR was observed in 75/152 patients (49.3%).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1) CML patients under treatment with combination therapy with medication other than imatinib 2) CML patients with history of treatment with tyrosine kinase inhibitor other than imatinib 3) Patients with history of hematopoietic stem cell transplantation 4) Patients with severe or uncontrollable complications 5)Patients whom a study physician judges not suitable for participation in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ratio of patients who achieved CMR (<= 0.0032%) in MMR patients, defined by major BCR-ABL mRNA quantitative PCR assay (international scale)
- Secondary Outcome Measures
Name Time Method